AbbVie's SKYRIZI achieves significant endoscopic remission in Phase 3 Crohn's disease trials, bolstering the company's immunology portfolio and growth outlook.
AbbVie's SKYRIZI has demonstrated significant clinical efficacy in Phase 3 AFFIRM trials for Crohn's disease, specifically achieving superior rates of endoscopic remission and ulcer-free endoscopy compared to placebo. These results reinforce the drug's competitive positioning and support the company's long-term growth strategy within its immunology portfolio.
SKYRIZI demonstrated higher rates of endoscopic remission and ulcer-free endoscopy compared to placebo.
Yes, these results build on previously reported week 12 findings where SKYRIZI achieved superiority in co-primary endpoints of clinical remission.
AbbVie reports positive Phase 3 AFFIRM data for SKYRIZI, demonstrating superior endoscopic remission rates in patients with Crohn's disease compared to placebo. These results reinforce the drug's clinical efficacy and support the company's long-term growth trajectory in the immunology market.
The study shows that SKYRIZI achieves higher rates of endoscopic remission and ulcer-free endoscopy in Crohn's disease patients compared to placebo.